-transparent.png){kind=logo}
Between 1982 and 1989 we identified 47 subjects with spuriously increased concentrations of free thyroxin (FT4) or free triiodothyronine (FT3) related to autoantibody interference in analog FT4 and (or) FT3 methods. The incidence of autoantibody interference observed during one year (1988) was 1 in 2460. In the subjects identified, 51% and 11%, respectively, showed an increased binding of radiolabeled T4 or T3 analog alone; 38% had an increased binding of both. Of 36 patients tested, 71% had autoantibodies to thyroglobulin and microsomal fraction of the thyroid, 19% to microsomal fraction alone, and 9.5% to thyroglobulin alone. In eight subjects, spuriously increased FT4 concentrations were reported with the following FT4 methods (in decreasing order of interference): Coat-A-Count, Amerlex-M, Amerlite, Seria, Magic Lite, Amerlex-MAB. In the same eight subjects, Amerlex-M and Seria reported spuriously increased concentrations of FT3.
R John, and
R Henley, and
D Shankland
June 1983,
Clinical chemistry,
R John, and
R Henley, and
D Shankland
May 1988,
Clinical chemistry,
R John, and
R Henley, and
D Shankland
May 1991,
Clinical chemistry,
R John, and
R Henley, and
D Shankland
December 1988,
Clinical chemistry,
R John, and
R Henley, and
D Shankland
June 1982,
Clinical chemistry,
R John, and
R Henley, and
D Shankland
March 1983,
Clinical chemistry,
R John, and
R Henley, and
D Shankland
August 1983,
Clinical chemistry,
R John, and
R Henley, and
D Shankland
November 1953,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
R John, and
R Henley, and
D Shankland
April 1966,
Journal of pharmaceutical sciences,
R John, and
R Henley, and
D Shankland
January 1984,
Clinical chemistry,
